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Abstract

Currently, 1 in 13 people (264 million people) are diagnosed in the world with
anxiety disorder. Anxiety is a disorder that causes random or triggered panic attacks
due to an imbalance of neurotransmitters in the limbic system of the brain. Marijuana
(Cannabis sativa) contains high levels of delta-9-tetrahydrocannabinol (THC). THC acts
as a neurotransmitter and is able to attach to molecules called cannabinoid receptors on
neurons, activate them, which results in changes in mental and physical functions. The
neural communication network used by THC neurotransmitters is known as the
endocannabinoid system. The endocannabinoid system and the limbic system are
interconnected and share the use of cannabinoid receptors. Therefore, THC derived
medications has a potential to alleviate anxiety symptoms by rebalancing of
neurotransmitters in the limbic system.
Introduction
Marijuana, also known as Cannabis, contains a psychoactive component called
delta-9-tetrahydrocannabinol (THC), which essentially causes the “high” effect known
from consuming or smoking the plant. Marijuana also contains cannabidiol (CBD) which
has shown some medically beneficial effects on serious neurological disorders and
more (Zou et al., 2018). C. sativa is tall, long, and with narrow leaves, and provides an
energizing, stimulating effect, producing a greater amount of THC than CBD. On the
other hand, C. indica is a short and broad plant with thick, dense leaves, and provides a
more relaxing, calming effect, producing an equalized ratio between THC than CBD
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(McPartland, 2017). C. sativa strain is used in the medical industry because of its ratios
between THC and CBD, which is more ideal to reach more audiences including
children. The C. sativa strains’ low CBD and high THC content will cause more of an
effect on the CB1 and CB2 production, which comes primarily from the

THC

component. Marijuana is trending in the medical world, and recently, research has
proven that use of cannabinoids might be beneficial on curing and/or alleviating some of
the most common diseases/disorders, including anxiety.
Anxiety is a psychiatric disorder that causes panic and apprehension in response
to stress. It can be caused by various sources: trauma, genetic inheritance, fear/
phobias, environmental stress, among other things. The disorder effects 18.1% of the
U.S. population each year, totaling up to more than 40 million people (ADAA). Anxiety
causes chemical changes in the limbic system, which includes the amygdala,
hippocampus and the hypothalamus of the brain (Zou et al., 2018).
The endocannabinoid system (ECS) is a multi-region complex of several brain
areas: medial prefrontal complex, amygloid complex, hippocampus, and the dorsal
periaqueductal gray (Murrough, 2015) and overlaps 2/3 of the limbic regions. Current
research on the two agonist cannabinoid receptors, CB1 and CB2, are helping to
understand the role of cannabis on anxiety.
In this review, research about the endocannabinoid system, CBR receptors &
signaling within the central nervous system, the significance of the overlapping systems
between ECS and anxiety, and how cannabinoids & related medicines are being used
and examined for anxiety will all be analyzed.
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The Endocannabinoid System

Did you know that everyone has an endocannabinoid system? The ECS is selfgoverned and has receptors all over the body, your body even produces a very small
number of natural cannabinoids. However, when a person consumes THC from
marijuana in whichever form they prefer, there ends up being excess of cannabinoids in
the system, disrupting the balance. Cannabinoids don’t only just effect the brain, but
other regions of the body where the receptors reside.
The ECS involves two cannabinoid receptor that cells in the body express called
CB1 and CB2 (these are agonists), these are found in the immune system and very
abundant in the central nervous system. The agonists are what really establish the
connection between cannabis and the body, these agonists initiate a response once its
combined with a receptor (Zou, 2015). It is possible that anxiety can be alleviated with
medical marijuana (sativa) use due to how closely related the systems are and the
interactions and overlap between them.
Endocannabinoid system overlapping the limbic system of Anxiety

The idea of anxiety is linked with fear, and fear is a result of the body responding
to a possibly dangerous stimulus, to lead the organism to promote survival (Ruehle et
al., 2011). Therefore, anxiety is natural, although disruptions in the balance of the
neurotransmitters can cause neurological dysfunctions which the illness anxiety is.
Anxiety is frequent occurrence of one or more stimuli triggering the exhausting
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symptoms of anxiety, when it's not of dire need to express these symptoms. Those who
suffer from anxiety disorder, have an imbalance in the emotional area of the brain of the
limbic system (Martin et al., 2013). The limbic system contains some of the same areas
of the brain of the endocannabinoid system, controlling the body’s perception of senses,
pain, fear, stress, mood and more. The crossover of the two systems in the same brain
regions play an important role in how the ECS functions in relation in how cannabinoids
can effect anxiety. Those with anxiety disorder will have decreased inhibitory signaling
or increased excitatory neurotransmission in the communication between brain cells via
gamma-amino-butyric acid (GABA - reducing neuronal activity) or glutamate (increasing
neuronal activity). When activated by CB1Rs, GABA will have anxiogenic response,
inducing anxiety. On the other hand, glutamate creates an anxiolytic response, reducing
anxiety. These two neurotransmitters are known in the ECS for possessing cannabinoid
CB1 receptors in the axon terminals, when activated, CB1 can play its role in inhibiting
the production of GABA by controlling its release (Laaris et al., 2010), therefore, causing
a push against the unbalanced neurotransmitters and reducing anxiety’s effects.
However, just like everything else, CB1R agonists can have pros and cons; too many of
the receptors can cause anxiogenic effects, and not enough agonists can lead to
anxiolytic effects (Ruehle et al., 2011). Theses two transmitters do not work together, so
to regulate anxiety, the focus point is to regulate the both of them equally so that no
anxiogenic response occurs.
Studies was conducted by several research teams to test the conation between
cannabinoid receptors and the neurotransmitters, there were three main tests used to
analyze the levels of stress the subject mice: light/dark box test, elevated plus-maze,
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and Vogel conflict test. After a knockout of CB1R was analyzed, comparing wild type
mice to mice with the knock out of CBRs, resulted in an anxiogenic response in the
mice with the knock out. Although, the study resulted in a strong decrease or increase of
an anxiety response, the absence of the CB1R solely depends on which
neurotransmitter is more abundant (Ruehle et al., 2011). This study expresses how
cannabinoid receptors are bimodal when expressing anxiety, because of the
neurotransmitters they interact with. Even directly injected THC into different areas of
the brain result in two different dominances of the neurotransmitters. When injected into
the prefrontal cortex, there is a anxiolytic effect, versus when injected in the basal
amygdala, theres an anxiogenic response (Ruehle et al., 2011). A possible explanation
goes along the lines of expression of a dominant neurotransmitter in various areas of
the limbic system this all connect to how anxiety works in the body, these results may
vary. Another study conducted by Haller and her team to observe the effects of agonist
cannabinoids (WIN-55,212) compared to the cannabinoid antagonist (AM-251) in mice
and wistar rats, they believed that the variations of the antagonist-agonist interactions
were species related. Which makes sense because some animals can be more fearful
(increased anxiety) than other animals. For example, smaller, more preyed on animals
vs larger, predatory animal would have different triggers for anxiety. In the study, the
team hypothesized that the species’ effects from cannabinoids were sensitive on
expression of GABA and glutamate on anxiety (Haller et al., 2007). During the control
period of the experiment, the researchers regulated the mice and rats in a stable lab
conditions, so that they can become used to it, and already they seen environmental
factors that could effect the experiment (hierarchy/ social status between the animals),
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so they separated every subject to focus solely on the behavior, instead of
environmental factors. They studied several series of experiments, comparing and
contrasting these effects of higher and lower concentration (0.3 mg/kg and 1 mg/kg) of
agonists or (1mg) antagonist, light and dark, isolation and combination, and functionality
of the subjects in the plus maze, the results followed: the antagonist had an anxiogenic
effect on the mice, closed-arm entries were not effected (P> 0.2), and open-arm entries
were significantly reduced compared to the control (P<0.003 & P= 0.057); on the other
hand, rats didn’t respond to the antagonist as the mice, closed-armed entries weren’t
significantly different (P< 0.5), open-armed entries weren’t significantly different (P<0.7)
(Haller et al., 2007). In the mice specifically, the results show that the WIN-55,212
agonist decreased anxiety, but on the other hand, the same agonist created an increase
in anxiety in the rats. The article compares the activation of cannabinoid receptors in
several species, and there is a significant different in what species’ CBR1/CBR2 will
release which neurotransmitter. Fortunately, mice and humans have the same reactions
when the cannabinoid receptors 1 and 2 are activated.
Cannabinoid receptors and signaling in the limbic system

The receptors of the endocannabinoid system are very much expressed
throughout the central nervous system with or without the assistance of cannabis. The
CB1 and CB2 receptors are G-protein-coupled receptors (GCPRs), agonists within the
endocannabinoid system that are represented across neurological systems, they
function together to degrade metabolism, cellular uptake, and endocannabinoid
biosynthesis (Pertwee, 2012). The other endocannabinoids that are produced by the
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body, anandamide (AEA) and 2-arachidonoylglycerol (2-AG) help activate the CB1 and
CB2 receptors and begin the up-regulation/ down-regulation of the psychoactive
neurotransmitter balance in the body (Mouhamed et al., 2018). CB1 differs from CB2
because it is localized at the presynaptic terminals, hence their function to inhibit
neurotransmitter release and regulate cytokine release; whilst CB2 receptors
concentrate in the immune system (Pertwee, 2005). These synapses occur with the
brain region of the limbic system specifically the amygdala, which is why it’s an
important location for intertwining the two systems. The amygdala controls fear
response, expressing as symptoms of anxiety, the synapses here are extremely
important to the overall expression of GABA and glutamate to determine what actually
triggers symptoms in which part of the amygdala. As previously mentioned, the
neurotransmitters GABA and glutamate are expressed to create an influx within the
nervous system to directly cause anxiogenic or anxiolytic effects on the body. When
CB1 is activated, it usually leads to inhibition of release of GABA, using the agonist (as
mentioned previously) WIN-55,212 (Ruehle, et al., 2012), this method can be very
efficient in the control of anxiogenic effects. However, THC can manifest both anxiolytic
and anxiogenic characteristics because when its bound to CB1 receptors, release of
both GABA and glutamate compounds (Pertwee, 2005), so it is definitely possible for
marijuana to cause anxiety or increase its symptoms. Although, if properly regulated by
dosage, and even singling out THC components, it is possible to correct the imbalance
and focus on releasing only GABA or only glutamate to properly treat one with anxiety,
but only if its known which neurotransmitter is causing the imbalance. The process of
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targeting requires more research for progress on using THC neurological aspect for
treatment of anxiety.
Drugs targeting cannabinoid receptors to treat anxiety

As the states of the United States are slowly legalizing the use of medicinal
marijuana, the government has set very strict guidelines and requirements in the
lengthy process from the specific bud to the patient. The most complicated part is
educating the physicians on proper criteria on how to prescribe the doses. It is
recommended to start low to determine the level of euphoria that the patient
experiences to figure out the amount that is best for the patient to acquire and to avoid
too high of a dose that can impair cognition of the patient (Murrough et al., 2015).
Calcium is a key factor in the middle of the these processes, when AEA, 2-AG, or THC
bind with CB1 in the presynaptic terminal, it regulates the amount of calcium then
decreases the release of neurotransmitters to travel to the post synaptic terminal.
Interferences in this process can lead to many different types of reactions in the body,
which is not ideal, therefore controlling this regulation is what the drugs are needed to
do. As we know, psychological disorders are usually caused by disfunction or certain
imbalances in the neurotransmitters produced in the brain, here is when the
endocannabinoid system can come into play. The relation between two systems have
been thoroughly researched, and in some cases, there will be up regulation in the
endocannabinoid system that causes symptoms of a disorder/disease in which
antagonists can aid in down regulation in the neurological balance (Pertwee, 2005),
essentially rebalancing the transmitters and stopping symptoms. Pharmacologists will
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have to identify specific receptors involved and location of the imbalances to then know
what drug and its abundance can solve the issue. In the case of anxiety, drugs already
established target serotonin and GABA in the body to regulate symptoms such as:
headache pains, insomnia, diarrhea/nausea, appetite decrease, fatigue and cognition
issues (Mouhamed et al., 2018). Big “pharma” has worked on synthesizing the creating
a version of THC that can be easily administered and can avoid the other effects of
marijuana without actually using marijuana, hence there were be neurological effects
without the side effects. One of the top choice of treatments for anxiety already in place
are benzodiazepines, which enhance the effects of GABA, leading to calming the
excited signaling of the neuronal synapses overall (slowing down the release of more
neurotransmitters) (Griffin, et al., 2013), which can be used synergistically with other
possible treatments for a strong effect on rebalancing the neurotransmitters.
Conclusion
In conclusion, GABA and glutamate are the key components to bridging the gap
between the endocannabinoid system and the limbic system. The secret to balancing
the neurotransmitters caused by anxiety lies within the mystery of how the receptors
release neurotransmitters, which ones and how much. Once that has been discovered,
scientists can pin point the stimulating factor from marijuana in the THC molecules to
regulate the imbalance and virtually solving the chemical issue with anxiety patient.
Therefore, marijuana derived treatments can help alleviate symptoms of anxiety,
although there is much more research needed to done to achieve that goal. There are
many people in the world suffering from anxiety, and the numbers are increasing.
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Something needs to be done to lower the stats on this disorder, because it has potential
to lead to more serious disorders and illnesses.
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